ESMO Consensus Guidelines: Non-small-cell lung cancer first-line/second and further lines in advanced disease

Published in 2014 - Ann Oncol (2014) doi: 10.1093/annonc/mdu123
Authors: B. Besse, A. Adjei, P. Baas, P. Meldgaard, M. Nicolson, L. Paz-Ares, M. Reck, E.F. Smit, K. Syrigos, R. Stahel, E. Felip, S. Peters

This report from the 2nd ESMO Consensus Conference on Lung Cancer covers all patients (regardless of NSCLC mutational status): chemotherapy in asymptomatic patients, anti-angiogenic treatment, to switch or to continue maintenance treatment, elderly patients, and systemic treatment for bone metastases, NSCLC aberrations: first-line treatment for EGFR mutated and ALK rearranged NSCLC, optimal management of brain metastases at diagnosis, and recommendations for later lines, and emerging biomarkers and secondary resistance: re-biopsy and treatment options for patients with ROS1, RET, BRAF or HER2 alterations after standard treatment.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings